This study evaluates an investigational treatment called LBP-EC01, which uses bacteriophages (viruses that target bacteria) to treat acute UTIs caused by drug-resistant E. coli. Participants will receive either the study drug or a placebo, both alongside standard antibiotic therapy. The goal is to find a safe and more effective way to treat UTIs when traditional antibiotics may not work.
Eligibility:
• Adults with a recent history of UTIs caused by drug-resistant E. coli
• Currently experiencing an uncomplicated UTI
• Not currently taking antibiotics to treat this infection